Caladrius Biosciences (NASDAQ:CLBS) Stock Crosses Above 50-Day Moving Average of $2.86

Caladrius Biosciences Inc (NASDAQ:CLBS)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.86 and traded as high as $2.33. Caladrius Biosciences shares last traded at $2.31, with a volume of 485 shares trading hands.

Several analysts recently weighed in on the company. Zacks Investment Research raised Caladrius Biosciences from a “sell” rating to a “hold” rating in a report on Monday, May 27th. WBB Securities assumed coverage on Caladrius Biosciences in a report on Tuesday, May 14th. They issued a “speculative buy” rating and a $6.75 price objective for the company. Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Caladrius Biosciences in a report on Sunday, May 12th. Finally, ValuEngine lowered Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $9.25.

The company’s fifty day moving average is $2.83.

Caladrius Biosciences (NASDAQ:CLBS) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). On average, equities analysts anticipate that Caladrius Biosciences Inc will post -1.66 EPS for the current fiscal year.

An institutional investor recently bought a new position in Caladrius Biosciences stock. Wesbanco Bank Inc. bought a new stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $36,000. Wesbanco Bank Inc. owned about 0.10% of Caladrius Biosciences at the end of the most recent quarter. Institutional investors own 7.59% of the company’s stock.

Caladrius Biosciences Company Profile (NASDAQ:CLBS)

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Article: Front-End Load

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.